Companies: 10,795·Total market cap: $144.5T
Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

TKPHFOTCHealthcare● Active
$32.60
+$2.13(+6.99%)
Market Cap$51.5B
P/E Ratio—
52W High$39.2
52W Low$26.33
Overview
Stock ranking:Drug Manufacturers - Specialty & Generic·Healthcare·View All Market Cap Rankings →

Takeda Pharmaceutical Company Limited (TKPHF) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · TKPHF · as of Jun 8, 2026

Key Statistics

EPS (TTM)$121.93tkphf eps ttm · tkphf earnings per shareEarnings history
PE Ratio (TTM)0.3×tkphf pe ratio ttm · tkphf price to earningsPE Ratio deep dive
Revenue (TTM)$4.51Ttkphf revenue ttm · tkphf annual revenueFull revenue history
Dividend Yield3.33%does tkphf pay dividends · tkphf dividend yieldDividend history
Shares Outstanding1.58Btkphf shares outstanding · tkphf floatShares outstanding history
Next EarningsJul 30, 2026Est.tkphf earnings date · tkphf next earningsEarnings history

Explore Takeda Pharmaceutical Company Limited Data

tkphf stock data · financials
Market Cap$51.5Btkphf market cap · tkphf valuation
Analyst Forecast$— · Buy
Dividends3.33%does takeda pharmaceutical company limited pay dividends · tkphf dividend yield
Revenue$4.53T-1.04%takeda pharmaceutical company limited annual revenue · tkphf revenue
EarningsEPS $123.03+79.97%tkphf earnings · tkphf eps
PE Ratio0.3×tkphf pe ratio · tkphf price to earnings

Financial Snapshot

Full Financials
FY 2026Revenue$4.53T▼ 1.04% YoY
202420252026
takeda pharmaceutical company limited revenue · tkphf revenue 2026
FY 2026Net Income$192.97B▲ +78.79% YoY
202420252026
takeda pharmaceutical company limited net income · tkphf profit 2026
FY 2026EPS$123.03▲ +79.97% YoY
202420252026
tkphf eps · takeda pharmaceutical company limited earnings per share 2026
TTM:Revenue: $4.51TNet Income: $191.70BEPS: $121.93View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis tkphf a buy · tkphf analyst rating
Strong Buy
0
Buy
4
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$—Low
$32.60Current
$—Avg Target
$—High
tkphf price target · tkphf 12 month forecast

Total: 5 · Buy rate: 80.0%

Stock Performance

Full History
1D+6.99%
1W+6.99%
1M+1.09%
3M-5.94%
YTD+5.74%
1Y+10.88%
5Y-3.18%

About Takeda Pharmaceutical Company Limited

CEOChristophe Weber
IPO DateJun 25, 2008
Employees49,281
CountryJP
Websitetakeda.com

Takeda Pharmaceutical Company Limited an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medic…

Drug Manufacturers - Specialty & GenericHealthcareOTCJP

what is takeda pharmaceutical company limited · tkphf stock overview · takeda pharmaceutical company limited company profile · who is takeda pharmaceutical company limited ceo · tkphf OTC · takeda pharmaceutical company limited headquarters · takeda pharmaceutical company limited business segments

About Stock Overview & Key Data

Takeda Pharmaceutical Company Limited (TKPHF) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on OTC since Jun 25, 2008. As of the latest trading session, TKPHF stock price is $32.60, with a market capitalization of $51.5B. The stock has returned +10.88% over the past 12 months and +5.74% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Takeda Pharmaceutical Company Limited stock is Buy, with an average 12-month price target of $—. In fiscal year 2026, Takeda Pharmaceutical Company Limited reported revenue of $4.53T and net income of $193.0B. For detailed data — including Takeda Pharmaceutical Company Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Takeda Pharmaceutical Company Limited (TKPHF) stock price is $32.60. The stock is traded on OTC under the ticker symbol TKPHF. The 52-week range is $26.33 – $39.20.

TKPHF stock priceTKPHF quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice